TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Abbott’s Navitor TAVR valve linked to positive real-world outcomes
The intra-annular, self-expanding Navitor valve gained FDA approval in 2023 for the treatment of high-risk heart patients with severe aortic stenosis. This analysis explores its early impact on patient care.
TAVR’s next big challenge: Providing consistent relief for heart patients with aortic regurgitation
TAVR has already transformed care for patients with severe aortic stenosis. Will it make a similar impact on the treatment of aortic regurgitation?
Low-volume operators linked to worse outcomes after TAVR, M-TEER
Researchers tracked data from more than 400,00 patients, sharing their findings in JAMA Cardiology.
Judge blocks Edwards’ JenaValve acquisition—FTC calls it a ‘major win’ for Trump administration
The FTC argued that the $945M deal, first announced in 2024, was "anticompetitive." A federal judge agreed.
TAVR, other interventional procedures may provide value for patients with carcinoid heart disease
These patients are typically treated with surgery, but those procedures carry their own risks that clinicians would prefer to avoid.

Abbott’s Navitor TAVR valve linked to positive real-world outcomes

The intra-annular, self-expanding Navitor valve gained FDA approval in 2023 for the treatment of high-risk heart patients with severe aortic stenosis. This analysis explores its early impact on patient care.

cardiologist patient heart compensation starting salary 2022 interventional cardiologist

TAVR’s next big challenge: Providing consistent relief for heart patients with aortic regurgitation

TAVR has already transformed care for patients with severe aortic stenosis. Will it make a similar impact on the treatment of aortic regurgitation?

Low-volume operators linked to worse outcomes after TAVR, M-TEER

Researchers tracked data from more than 400,00 patients, sharing their findings in JAMA Cardiology.

court judge gavel business man bankruptcy lawsuit

Judge blocks Edwards’ JenaValve acquisition—FTC calls it a ‘major win’ for Trump administration

The FTC argued that the $945M deal, first announced in 2024, was "anticompetitive." A federal judge agreed.

TAVR, other interventional procedures may provide value for patients with carcinoid heart disease

These patients are typically treated with surgery, but those procedures carry their own risks that clinicians would prefer to avoid.

Newsweek ranked the 50 best heart hospitals in the world

Cardiologists perform first procedure of its kind to prevent coronary obstruction after TAVR

A vulnerable heart patient required TAVR, but he faced an extremely high risk of coronary obstruction. Leaflet modification and snorkel stenting were not possible, so the group turned to a brand new treatment option: the VECTOR procedure.

TAVR remains a viable treatment strategy for cancer patients

Improvements in care have resulted in a growing number of patients who go on to be diagnosed with both cancer and severe aortic stenosis. TAVR appears to be an effective treatment option for those individuals, and it may help them go on to receive life-saving cancer therapies.

business marketing meal lunch food group project team building

TAVR or SAVR? Market competition may be influencing these decisions

Hospitals located in more competitive markets may be more likely to perform TAVR instead of SAVR, according to a new analysis of more than 130,000 patients. Is this a reason for concern?